Patents Examined by Karen Cochrane Carlson
  • Patent number: 11174300
    Abstract: Provided herein are non-naturally occurring polypeptides comprising a sequence of a fragment of a collagen and recombinant cells containing heterologous nucleic acid sequences encoding the non-naturally occurring polypeptides. Further provided herein are animal-free methods of generating and purifying such non-naturally occurring polypeptides using microorganisms, preferably from bacterial cells.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: November 16, 2021
    Assignee: GELTOR, INC.
    Inventors: Nikolay Ouzounov, Jeffrey R. Mellin, Julia Co
  • Patent number: 11168110
    Abstract: Herein is reported a method for obtaining a polypeptide in monomeric form comprising the steps of a) providing a solution comprising the polypeptide in monomeric form and in aggregated form, wherein the ratio of monomeric to aggregated form is 4:1 or less as determined by size exclusion chromatography, b) performing a mixed-mode chromatography in bind-and-elute mode, or a hydrophobic interaction chromatography in flow-through mode, or a size-exclusion chromatography, and c) performing a weak cation exchange chromatography in bind-and-elute mode or flow-through mode, and thereby obtaining the polypeptide in monomeric form.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: November 9, 2021
    Inventors: Monika Baehner, Adelbert Grossmann, Stefan Hepbildikler
  • Patent number: 11149279
    Abstract: Disclosed is a gene therapy DNA vector VTvaf17 for genetic modification of animal and human cells having SEQ ID No. 1, and methods for its synthesis, involving constructing vectors containing a promoter region of human elongation factor EF1A, a polylinker with sites for restriction endonucleases, a transcription terminator, a polyadenylation sequence of human growth factor, a regulatory element of transposon Tn10 allowing for antibiotic-free positive selection, an origin of replication, and a kanamycin resistance gene. Escherichia coli strain SCS110-AF is also provided by the present invention. The method for creating the strain involves constructing a linear DNA fragment containing regulatory element of transposon Tn10, a levansucrase gene, sacB, a chloramphenicol resistance gene, and two homologous sequences. The E. coli cells are transformed by electroporation and clones surviving chloramphenicol are chosen.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: October 19, 2021
    Inventor: Natalia Savelieva
  • Patent number: 11142555
    Abstract: Provided herein are compositions and methods for producing recombinant milk proteins, as well as food compositions comprising the same. In aspects, the recombinant milk proteins of the disclosure are recombinant fusion proteins comprising casein and beta-lactoglobulin.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: October 12, 2021
    Assignee: Nobell Foods, Inc.
    Inventors: Viviane Lanquar, Magi El-Richani
  • Patent number: 11134681
    Abstract: The present invention is generally directed to fusion proteins containing a targeting sequence that targets the fusion protein to the exosporium of a Bacillus cereus family member. The invention also relates to recombinant Bacillus cereus family members expressing such fusion proteins, formulations containing the recombinant Bacillus cereus family members expressing the fusion proteins. Methods for stimulating plant growth and for protecting plants from pathogens by applying the recombinant Bacillus cereus family members or the formulations to plants or a plant growth medium are also described. The invention also relates to methods for immobilizing spores of a recombinant Bacillus cereus family member expressing a fusion protein on plant roots.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: October 5, 2021
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Katie Thompson
  • Patent number: 11130784
    Abstract: The present invention relates generally to methods for producing microcystin and recombinant cells capable of producing microcystin. The recombinant cells express exogenous microcystin synthase polypeptides under the control of an exogenous promoter, and further express an exogenous phosphopantethienyl transferase (PPTase). The present invention further relates to microcystin as produced in recombinant cells by the methods described herein.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: September 28, 2021
    Assignee: NewSouth Innovations Pty Ltd
    Inventors: Brett Neilan, Tianzhe Liu, Rabia Mazmouz, Sarah Ongley
  • Patent number: 11123413
    Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 21, 2021
    Assignee: Synthetic Biologies, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • Patent number: 11124781
    Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.
    Type: Grant
    Filed: June 22, 2019
    Date of Patent: September 21, 2021
    Assignee: Bioasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Patent number: 11124779
    Abstract: The present invention includes compositions and methods for detecting, treating and preventing renal and pancreatic diseases and disorders.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: September 21, 2021
    Assignee: Yale University
    Inventor: Gary Desir
  • Patent number: 11116796
    Abstract: This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: September 14, 2021
    Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Alan Bird
  • Patent number: 11104924
    Abstract: A novel modified polypeptide having an isopropylmalate synthase activity, a polynucleotide encoding the same, a microorganism comprising the polypeptide, and a method of producing L-leucine by culturing the microorganism.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: August 31, 2021
    Assignee: CJ Cheiljedang Corporation
    Inventors: Ji Hye Lee, Byeong Cheol Song, Ae Ji Jeon, Jong Hyun Kim, Hye Won Kim
  • Patent number: 11091380
    Abstract: Provided herein are compositions and methods that can remove, metabolize, or degrade a hydrocarbon in an area that is contaminated by hydrocarbons. Methods for bioremediation of an area such as an area of land, a body of water, or a shoreline that are contaminated by a hydrocarbon, such as from a crude oil spill are also described. The compositions and methods described herein can be used on natural flora and fauna as well as manmade materials that are contaminated by a hydrocarbon.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: August 17, 2021
    Inventor: Janet Angel
  • Patent number: 11085053
    Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: August 10, 2021
    Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
  • Patent number: 11078245
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 3, 2021
    Inventor: Xue-Ping Wang
  • Patent number: 11078277
    Abstract: The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: August 3, 2021
    Inventors: Thierry Levade, Bruno Segui, Florie Bertrand, Julia Rochotte, Anne Montfort, Nathalie Andrieu-Abadie, Celine Colacios Viatge, Nicolas Meyer
  • Patent number: 11071771
    Abstract: The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: July 27, 2021
    Assignee: Kodiak Sciences Inc.
    Inventors: Daniel Victor Perlroth, Stephen A. Charles, Wayne To, Xiaojian Huang, Martin Linsell, Didier Benoit
  • Patent number: 11060078
    Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: July 13, 2021
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
  • Patent number: 11053491
    Abstract: A protein construct including a gene encoding a light-sensitive protein fused to at least one of either a low complexity sequence, an intrinsically disordered protein region (IDR), or a repeating sequence of a linker and another gene encoding a light-sensitive protein. Among the many different possibilities contemplated, the protein construct may also advantageously include cleavage tags. This protein construct may be utilized for a variety of functions, including a method for protein purification, which requires introducing the protein construct into a living cell, and inducing the formation of clusters by irradiating the construct with light. The method may also advantageously include cleaving a target protein from an IDR, and separating the clusters via centrifuge. A kit for practicing in vivo aggregation or liquid-liquid phase separation is also included, the kit including the protein construct and a light source capable of producing a wavelength that the light-sensitive protein will respond to.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: July 6, 2021
    Inventors: Cliff Brangwynne, Jared Toettcher, Yongdae Shin
  • Patent number: 11052136
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound selected from the group consisting of: a) a polypeptide of SEQ ID NO:1, b) a functionally equivalent variant of the polypeptide according to a), c) a polynucleotide encoding a) or b), d) a vector comprising a polynucleotide according to c), e) a cell capable of secreting into the medium a polypeptide according to a) or b), and f) a nanoparticle comprising the polypeptide according to a) or b) and a pharmaceutically acceptable excipient. The invention also relates to the use of said compounds or pharmaceutical compositions for treatment and/or prevention of ischemia injury or ischemia/reperfusion injury in a subject.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: July 6, 2021
    Inventors: Lina Badimon Maestro, Judit Cubedo Ràfols, Gemma Vilahur Garcia, Teresa Padró Capmany
  • Patent number: 11053492
    Abstract: A system and method for reversibly controlling clustering of proteins around an engineered multivalent nucleus is disclosed. The system and method utilize clustering, which may be controlled by light activation or deactivation. The system and method enable the spatiotemporal control of protein supramolecular assemblies, including liquid-like droplets under some conditions, and solid-like gels under other conditions. The system and method can be utilized for segregating or locally concentrating desired proteins and/or RNA in cells or cell lysate, which may be useful for protein purification purposes, or for assembling single or multiple membraneless bodies within specific sub-regions of the cells. These synthetically assembled bodies may recruit both transgenic and endogenic proteins and other biomolecules, thus can be linked to affect and even trigger a plethora of cellular processes, including both physiological and pathological (e.g., protein aggregation) processes.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: July 6, 2021
    Inventors: Cliff Brangwynne, Dan Bracha